180147-34-6

Basic information

• Product Name: [2-(2-AMINO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: [2-(2-AMINO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER;Carbamic acid, N-[2-(2-aminophenyl)ethyl]-, 1,1-dimethylethyl ester
• CAS NO: 180147-34-6
• Molecular Formula: C₁₃H₂₀N₂O₂
• Molecular Weight: 236.31
• Mol File: 180147-34-6.mol

Chemical Properties

• Boiling Point: 397.0±25.0 °C(Predicted)
• Appearance: /
• Density: 1.077±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 12.61±0.46(Predicted)
• CAS DataBase Reference: [2-(2-AMINO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: [2-(2-AMINO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER(180147-34-6)
• EPA Substance Registry System: [2-(2-AMINO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER(180147-34-6)

Safety Data

• Hazardous Substances Data: 180147-34-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
[2-(2-AMINO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER is used as a key intermediate in the synthesis of various pharmaceutical compounds for its ability to interact with biological systems, contributing to the development of new drugs and medicines.
Used in Organic Synthesis:
In the field of organic synthesis, [2-(2-AMINO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER serves as a versatile building block, facilitating the creation of a wide range of organic molecules for various applications, including but not limited to pharmaceuticals, agrochemicals, and materials science.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 48108-93-6 β-(o-aminophenyl)ethylamine 
• 180147-33-5 [2-(2-nitrophenyl)ethyl]carbamic acid tert-butyl ester 
• 2973-50-4 2-aminophenylacetonitrile 
• 610-66-2 2-nitro-benzeneacetonitrile 

Downstream Products

• 672301-05-2 N-(4S)-{4-Amino-5-[2-(2-aminoethyl)phenylamino]-pentyl}-N'-nitroguanidine 
• 1201167-78-3 (S)-tert-butyl 2-(2-{9H-fluoren-9-ylmethylcarbamoyl}-5-nitroguanidinopentanamido)phenethylcarbamate 
• 479644-53-6 C₂₄H₄₁N₇O₆ 

Relevant articles and documents

Rational Remodeling of Atypical Scaffolds for the Design of Photoswitchable Cannabinoid Receptor Tools

Azobenzene-embedded photoswitchable ligands are the widely used chemical tools in photopharmacological studies. Current approaches to azobenzene introduction rely mainly on the isosteric replacement of typical azologable groups. However, atypical scaffolds may offer more opportunities for photoswitch remodeling, which are chemically in an overwhelming majority. Herein, we investigate the rational remodeling of atypical scaffolds for azobenzene introduction, as exemplified in the development of photoswitchable ligands for the cannabinoid receptor 2 (CB2). Based on the analysis of residue-type clusters surrounding the binding pocket, we conclude that among the three representative atypical arms of the CB2 antagonist, AM10257, the adamantyl arm is the most appropriate for azobenzene remodeling. The optimizing spacer length and attachment position revealed AzoLig 9 with excellent thermal bistability, decent photopharmacological switchability between its two configurations, and high subtype selectivity. This structure-guided approach gave new impetus in the extension of new chemical spaces for tool customization for increasingly diversified photo-pharmacological studies and beyond.

Cannabinoid receptor light-operated ligand and preparation method and application thereof

The invention relates to the technical field of biology, in particular to a novel cannabinoid receptor light-operated ligand and a preparation method and application thereof. Disclosed is the cannabinoid receptor light-operated ligand or the isomer prodrug, the solvate and the pharmaceutically acceptable salt of the cannabinoid receptor light-operated ligand, wherein the structural formula of thecannabinoid receptor light-operated ligand is A-linker-B; A is a transmembrane domain ligand structure, and B is a light-operated element; Linker is a subunit which is linear and has no activity on acannabinoid receptor light-operated ligand. According to the invention, the cannabinoid receptor ligand is integrated with azobenzene through a proper connector, so that the ligand configuration is changed under an illumination condition, and the activation or inhibition state of the cannabinoid receptor is regulated and controlled.

Effect of potential amine prodrugs of selective neuronal nitric oxide synthase inhibitors on blood-brain barrier penetration

Several prodrug approaches were taken to mask amino groups in two potent and selective neuronal nitric oxide synthase (nNOS) inhibitors containing either a primary or secondary amino group to lower the charge and improve blood-brain barrier (BBB) penetration. The primary amine was masked as an azide and the secondary amine as an amide or carbamate. The azide was not reduced to the amine under a variety of in vitro and ex vivo conditions. Despite the decrease in charge of the amino group as an amide and as carbamates, BBB penetration did not increase. It appears that the uses of azides as prodrugs for primary amines or amides and carbamates as prodrugs for secondary amines are not universally effective for CNS applications.

Selective neuronal nitric oxide synthase inhibitors

Peptidomimetic compositions for selective inhibition of neuronal nitric oxide synthase.

Aromatic reduced amide bond peptidomimetics as selective inhibitors of neuronal nitric oxide synthase

Nitric oxide synthase inhibitors could act as important therapies for disorders arising from overstimulation or overexpression of individual nitric oxide synthase (NOS) isoforms. But preservation of physiologically important nitric oxide functions require the use of isoform-selective inhibitors. Recently we reported reduced amide bond pseudodipeptide analogues as potent and selective neuronal nitric oxide synthase (nNOS) inhibitors (Hah, J.-M.; Roman, L. J.; Martasek, P.; Silverman, R. B. J. Med. Chem. 2001, 44, 2667-2670). To increase the lipophilicity a series of aromatic, reduced amide bond analogues (6-25) were designed and synthesized as potential selective nNOS inhibitors. The hypothesized large increase in isoform selectivity of nNOS over inducible NOS was not obtained in this series. However, the high potency with nNOS as well as high selectivity of nNOS over endothelial NOS was retained in some of these compounds (15, 17, 21), as well as good selectivity over inducible NOS. The most potent nNOS inhibitor among these compounds is N-(4S)-{4-amino-5-[2-(2-aminoethyl)-phenylamino]-pentyl}-N′- nitroguanidine (17) (Ki = 50 nM), which also shows the highest selectivity over eNOS (greater than 2100-fold) and 70-fold selectivity over iNOS. Further modification of compound 17 should lead to even more potent and selective nNOS inhibitors.